Traws Pharma (TRAW) Institutional Ownership $4.48 -0.21 (-4.48%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$4.79 +0.31 (+6.92%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Traws Pharma (NASDAQ:TRAW)CurrentInstitutional OwnershipPercentage7.95%Number ofInstitutional Buyers(last 12 months)6TotalInstitutional Inflows(last 12 months)$2.32MNumber ofInstitutional Sellers(last 12 months)0 Get TRAW Insider Trade Alerts Want to know when executives and insiders are buying or selling Traws Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data TRAW Institutional Buying and Selling by Quarter Traws Pharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/17/2025 Vestal Point Capital LP75,000$666K0.0%N/A2.055% 2/17/2025 Millennium Management LLC10,012$89K0.0%N/A0.274% 2/17/2025 Alyeska Investment Group L.P.116,714$1.04M0.0%N/A3.198% 2/14/2025 Boothbay Fund Management LLC28,431$252K0.0%N/A0.779% 2/13/2025 Renaissance Technologies LLC10,052$89K0.0%N/A0.275% 2/12/2025 Geode Capital Management LLC20,801$185K0.0%N/A0.570% (Data available from 1/1/2016 forward) TRAW Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of TRAW shares? During the previous two years, the following institutional investors and hedge funds held shares of Traws Pharma shares: Alyeska Investment Group L.P. ($1.04M), Vestal Point Capital LP ($666K), Boothbay Fund Management LLC ($252K), Geode Capital Management LLC ($185K), and Millennium Management LLC ($89K), Renaissance Technologies LLC ($89K).Learn more on TRAW's institutional investors. What percentage of Traws Pharma stock is owned by institutional investors? 7.95% of Traws Pharma stock is owned by institutional investors. Learn more on TRAW's institutional investor holdings. Which institutional investors have been buying Traws Pharma stock? The following institutional investors have purchased Traws Pharma stock in the last 24 months: Alyeska Investment Group L.P. ($116.71K), Vestal Point Capital LP ($75K), Boothbay Fund Management LLC ($28.43K), Geode Capital Management LLC ($20.80K), Renaissance Technologies LLC ($10.05K), and Millennium Management LLC ($10.01K). How much institutional buying is happening at Traws Pharma? Institutional investors have bought a total of 261,010 shares in the last 24 months. This purchase volume represents approximately $2.32M in transactions. Related Companies Skye Bioscience Institutional Ownership DBV Technologies Institutional Ownership Immunic Institutional Ownership Citius Oncology Institutional Ownership Galectin Therapeutics Institutional Ownership Inozyme Pharma Institutional Ownership Acumen Pharmaceuticals Institutional Ownership Entera Bio Institutional Ownership X4 Pharmaceuticals Institutional Ownership Cellectis Institutional Ownership This page (NASDAQ:TRAW) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
